Cushing Sydrome Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

(Albany, US) September 27, 2026- DelveInsight’s “Cushing Syndrome Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical-stage products. It also covers the Cushing Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Cushing Syndrome Pipeline? @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight

Key Takeaways from the Cushing Syndrome Pipeline Report

• On September 09, 2026, Sparrow Pharmaceuticals conducted a phase 2 trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
• DelveInsight’s Cushing Syndrome Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Cushing Syndrome treatment.
• The leading Cushing Syndrome Companies include Stero Therapeutics, Sparrow Pharmaceuticals, and others.
• Promising Cushing Syndrome Therapies such as SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, Levoketoconazole, mifepristone, CORT125134, and others.

Want to know which companies are leading innovation in Cushing Syndrome? @ Cushing Syndrome Clinical Trials Assessment

The Cushing Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Cushing Syndrome Pipeline Report also highlights the unmet needs with respect to the Cushing Syndrome.

Cushing Syndrome Overview

Cushing’s syndrome, or hypercortisolism is a hormonal disorder caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol. Causes of Cushing syndrome are typically divided into two basic categories: those that are adrenocorticotropic hormone (ACTH)-dependent and those that are ACTH-independent. It is a rare disorder and most commonly affects adults aged 20 to 50. The pituitary tumor overproduces ACTH and lacks hypothalamic-pituitary-adrenal (HPA) axis feedback regulation; thus, excessive amounts of cortisol are secreted from the adrenal glands. Prolonged systemic exposure to elevated cortisol levels results in a significant clinical burden in patients with CD due to comorbidities, increased mortality, and impaired health-related quality of life (HRQoL).

Cushing Syndrome Emerging Drugs

• Atumelnant: Crinetics Pharmaceuticals

Atumelnant (CRN04894) is a first-in-class, once-daily oral melanocortin-2 receptor (MC2R) antagonist being developed by Crinetics Pharmaceuticals for the treatment of ACTH-dependent Cushing’s syndrome. The therapy is designed to selectively block ACTH signaling at the adrenal gland, thereby reducing excess cortisol production while addressing the underlying disease mechanism. Recent findings from the ongoing Phase I/II study presented at ENDO 2026 demonstrated that atumelnant rapidly reduced early morning serum cortisol in all treated patients, with urinary free cortisol (UFC) remaining at or below the upper limit of normal in 3 of 6 participants after 10 days of treatment, including at a lower 40 mg once-daily dose. The drug was generally well tolerated, with most adverse events being mild to moderate and consistent with manageable adrenal insufficiency. Currently, the drug is in Phase II stage of its development for the treatment of Cushing’s syndrome.

If you’re tracking ongoing Cushing Syndrome Clinical trials, this press release is a must-read @ Cushing Syndrome Treatment Drugs

The Cushing Syndrome Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Cushing Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cushing Syndrome Treatment.
• Cushing Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cushing Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cushing Syndrome market.

Cushing Syndrome Companies

Stero Therapeutics, Sparrow Pharmaceuticals and others.

Cushing Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Cushing Syndrome Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Cushing Syndrome Pipeline Report covers it all @ Cushing Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Cushing Syndrome Pipeline Report

• Coverage- Global
• Cushing Syndrome Companies- Stero Therapeutics, Sparrow Pharmaceuticals and others.
• Cushing Syndrome Therapies- SOM230 LAR 30 mg, Pasireotide LAR, Osilodrostat, SPI-62, Mifepristone, Levoketoconazole, mifepristone, CORT125134 and others.
• Cushing Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cushing Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Cushing Syndrome Treatment landscape in this detailed analysis @ Cushing Syndrome Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Cushing Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cushing Syndrome– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Atumelnant: Crinetics Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cushing Syndrome Key Companies
21. Cushing Syndrome Key Products
22. Cushing Syndrome- Unmet Needs
23. Cushing Syndrome- Market Drivers and Barriers
24. Cushing Syndrome- Future Perspectives and Conclusion
25. Cushing Syndrome Analyst Views
26. Cushing Syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cushings-syndrome-pipeline-insight